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Abstract
Levels of glutathione are lower in the substantia nigra (SN) early in Parkinson’s disease (PD) and this may contribute to
mitochondrial dysfunction and oxidative stress. Oxidative stress may increase the accumulation of toxic forms of a-synuclein
(SNCA). We hypothesized that supplementation with n-acetylcysteine (NAC), a source of cysteine – the limiting amino acid
in glutathione synthesis, would protect against a-synuclein toxicity. Transgenic mice overexpressing wild-type human a-
synuclein drank water supplemented with NAC or control water supplemented with alanine from ages 6 weeks to 1 year.
NAC increased SN levels of glutathione within 5–7 weeks of treatment; however, this increase was not sustained at 1 year.
Despite the transient nature of the impact of NAC on brain glutathione, the loss of dopaminergic terminals at 1 year
associated with SNCA overexpression was significantly attenuated by NAC supplementation, as measured by
immunoreactivity for tyrosine hydroxylase in the striatum (p=0.007; unpaired, two-tailed t-test), with a similar but
nonsignificant trend for dopamine transporter (DAT) immunoreactivity. NAC significantly decreased the levels of human
SNCA in the brains of PDGFb-SNCA transgenic mice compared to alanine treated transgenics. This was associated with a
decrease in nuclear NFkB localization and an increase in cytoplasmic localization of NFkB in the NAC-treated transgenics.
Overall, these results indicate that oral NAC supplementation decreases SNCA levels in brain and partially protects against
loss of dopaminergic terminals associated with overexpression of a-synuclein in this model.
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder involving loss of specific subsets of neurons, including
dopaminergic neurons of the substantia nigra (SN). Though the
precise causes of PD are unknown, a large body of evidence
implicates mitochondrial dysfunction and oxidative stress [1,2].
Mitochondrial complex I function is impaired early in the course
of PD [3], and pharmacological inhibitors of complex I lead to
some of the features of PD in animal models [4,5], suggesting that
mitochondrial complex I deficiency may play a role in the
pathogenesis of PD. Complex I impairment leads to an increase in
the generation of reactive oxygen species (oxidative stress) [6–8],
consistent with reports of elevated markers of oxidative damage to
lipids, proteins, and DNA in the SN in PD [9]. This problem is
compounded by the fact that levels of glutathione, the predom-
inant intracellular thiol antioxidant, are severely deficient in the
SN at very early stages of PD [10,11].
SNCA toxicity also plays a central role in PD [12]. Although the
mechanisms of this toxicity are unknown, SNCA enhances
susceptibility to oxidative stress in a dopamine-dependent manner
[13]. This susceptibility may be due to the increased tendency of
SNCA to aggregate when exposed to oxidative stress [14–18], and
the stabilization of a toxic protofibril form of SNCA by oxidative
ligation of SNCA to dopamine [19]. If correct, then increased
oxidative stress due to early glutathione deficiency in the SN may
lead to enhanced toxicity of SNCA in dopaminergic SN neurons,
suggesting that strategies to increase glutathione or to block
oxidative stress by other means may protect against SNCA
toxicity.
We tested this hypothesis in an animal model of PD. Mice
overexpressing wild-type human SNCA from the platelet-derived
growth factor beta (PDGFb) promoter (line D PDGFb-SNCA) are
reported to develop motor impairments in association with
progressive loss of dopaminergic terminals [20]. Autosomal
dominant PD, which is clinically similar to idiopathic disease,
can be caused by a duplication or triplication of the normal SNCA
gene resulting in a global increase in brain SNCA expression [21–
23], demonstrating the relevance of this mouse model to human
disease. The impact of oral NAC supplementation from weaning
until 1 year of age was determined in these mice. NAC can raise
glutathione levels by acting as a cysteine donor in the synthesis of
glutathione [24]. NAC also has direct antioxidant activity and
additional effects on various cellular kinases and transcription
factors, including NFkB [25]. Systemic administration of NAC
increases brain levels of glutathione in mice [26–30], reduces
markers of oxidative damage [29], increases brain synaptic
mitochondrial complex I activity [28], and protects against MPTP
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humans [34] and has been proposed as a possible neuroprotective
agent in PD [35–37], but data in a chronic degenerative animal
model of PD has been lacking. The aim of this work was to test our
hypothesis that oral NAC supplementation could be neuroprotec-
tive in a chronic model of SNCA overexpression. The results
support this hypothesis, as striatal TH+ terminal density was
increased in NAC-treated SNCA overexpressing mice compared
to SNCA overexpressing mice on a control diet and this correlated
with a decrease in SNCA immunoreactivity in the brains of SNCA
overexpressing mice treated with NAC.
Results
Chronic oral treatment with NAC increases the density of
TH+ terminals in SNCA-overexpressing mice
Transgenic mice overexpressing SNCA showed a mean
decrease of 45.2% (95% CI 31.5–59.0%; p,0.001) in the
percentage of striatal area covered by tyrosine hydroxylase
positive (TH+) terminals compared to wild-type littermate controls
at 1 year of age (Fig. 1A, 1C,1E). This loss of TH+ terminals was
significantly attenuated by chronic oral NAC supplementation
beginning at 3 weeks of age (p=0.007; Fig. 1D, 1E). NAC
supplementation did not significantly alter the percentage of
striatal area covered by TH+ terminals in wild-type mice. As an
additional measure of dopaminergic terminals in the striatum, the
percentage of striatal area covered by dopamine transporter
positive (DAT+) terminals also was assessed (Fig. 1F). Similar to
the findings for TH+ terminals, the percentage of striatal area
covered DAT+ terminals was reduced by 43.2% (95% CI 12.0–
74.3%; p=0.015) in SNCA overexpressing mice compared to
littermate controls (Fig. 1F). There was a non-significant trend
towards protection against this loss of striatal DAT+ terminals by
chronic oral NAC supplementation (p=0.19).
Treatment with NAC Reduces Levels of SNCA in
PDGFb-SNCA Transgenic Mice
Mice treated with NAC exhibited an average 46.2% decrease
(95% CI 2.4–89.9%; p=0.0415) in human SNCA immunoreac-
tivity in the cortex (Fig. 2A–2E) compared to PDGFb-SNCA
transgenic mice treated with alanine. In addition, PDGFb-SNCA
transgenic mice treated with NAC also exhibited 94.5% fewer cells
containing SNCA-positive intracytoplasmic inclusions in the
cortex (Fig. 2F; p=0.0368), from an average of 109 cells/ROI
(SEM638.64) in PDGFb-SNCA transgenic mice supplemented
with alanine, to an average of 6 cells/ROI (SEM63.24) in
PDGFb-SNCA transgenic mice supplemented with NAC.
Similar results were also observed in the striata (Fig. 2G)o f
PDGFb-SNCA transgenic mice treated with NAC, where a 31.6%
decrease (95% CI 2.6–60.5% p=0.0371) in human SNCA
immunoreactivity compared to alanine treated animals was
observed. NAC treated PDGFb-SNCA transgenic mice also
exhibited 81.1% fewer cells containing SNCA-positive intracyto-
plasmic inclusions in the striatum (Fig. 2H; p=0.0013), from an
average of 4.42 cells/ROI (SEM60.4977) in PDGFb-SNCA
transgenic mice supplemented with alanine, to an average of 0.83
cells/ROI (SEM60.6365) in PDGFb-SNCA transgenic mice
supplemented with NAC.
NAC Treatment Increases Brain Glutathione Levels in the
Short-Term
To verify prior studies demonstrating that oral NAC supple-
mentation increases brain levels of glutathione in mice [38], we
determined glutathione levels in the SN and cortex of mice with ad
lib access to drinking water supplemented with 40 mM NAC for
5–7 weeks, beginning at 3 weeks of age. Control drinking water
was supplemented with 40 mM alanine. NAC supplementation
significantly increased SN levels of glutathione by a mean of 49%
(p=0.0133) in transgenic mice overexpressing SNCA (Fig. 3).
However, this initial increase in SN glutathione levels was not seen
in older mice that had been supplemented with NAC from
weaning until 12-months of age (Fig. 4). NAC had no effect on
glutathione levels in the cortex at either time-point (Fig. 3&4).
Treatment with NAC Increases Cytosolic localization of
NFkB
NAC can influence the activity of several transcription factors,
including inhibition of NFkB [25], increased activation of NFkB
has been observed in Parkinson’s disease models [39–41], and
inhibition of NFkB in glial cells has been proposed as a promising
neuroprotective strategy [42]. Nuclear and cytoplasmic fractions
were isolated from cortical tissues of wild-type and PDGFb-SNCA
mice. Proteins were separated by SDS-PAGE and probed with
anti- NFkB p65 antibody (Santa Cruz). An increased amount of
NFkB was seen in the cytoplasm of NAC-treated PDGFb-SNCA
cortical tissue compared to alanine-treated transgenics (Fig. 5A &
5B); accordingly, the amount of nuclear NFkB was decreased in
these animals (Fig. 5A & 5C). Total NFkB normalized to nuclear
and cytoplasmic loading controls did not vary significantly
between PDGFb-SNCA transgenic mice treated with either
alanine or NAC (data not shown).
NFkB is recruited to the PDGFb promoter in other tissues
[43,44], although this has not been demonstrated in brain.
Nevertheless, since SNCA is expressed from the PDGFb promoter
in this transgenic model we felt it was necessary to determine
whether NAC treatment may be affecting expression of transgenic
a-synuclein from the PDGFb promoter. Levels of PDGFb were
not significantly different between PDGFb-SNCA mice treated
with either alanine or NAC as determined by western blot (see
Supplementary Figure S1). Therefore the lowering of SNCA
protein levels seen in the PDGFb-SNCA transgenic mice after
treatment with NAC for one year is unlikely to be due to a
downregulation of the PDGFb promoter by NAC.
Effects of NAC Supplementation on Tests of Motor
Coordination
Each cohort of mice was tested on a battery of motor
coordination tests at 3, 6 and 12 months of age, including rotarod
testing, the pole test, and nest construction. We detected no
impairments of motor coordination in any of the groups tested at
any of the time points tested. Only data from the rotarod (and pole
test) at 12 months of age is shown (Fig. 6 & 7) and is presented in
a style to allow for comparison with previously published work
[20].
Discussion
In this study, we sought to assess the potential for neuropro-
tection by NAC in a chronic, transgenic mouse model of PD.
Multiple transgenic mouse models have been developed based on
overexpression of SNCA, each with advantages and limitations
[45,46]. We selected this model (line D PDGFb-SNCA) which
overexpresses wild-type human SNCA from the PDGFb promot-
er, in part, based on the fact that increased expression of wild-type
SNCA in humans can cause PD, as demonstrated in families with
autosomal dominant PD due to duplication or triplication of the
normal (wild-type) SNCA gene [21,22,47,48]. In addition, the line
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progressive loss of TH+ dopaminergic terminals in the striatum
and deficits in rotarod motor performance [20].
As previously reported, we find that mice overexpressing SNCA
display a significant loss of striatal TH+ terminals, and now report
the novel finding that chronic oral NAC supplementation protects
against this loss (Fig. 1E). A similar but non-significant trend was
seen for terminals labeled with anti-DAT antibody (Fig. 1F). It is
possible that upregulation of DAT expression in the remaining DA
terminals of SNCA overexpressing mice might mask the loss of
dopaminergic terminals by this measure, though it also is possible
that a difference would have been revealed with a larger number
Figure 1. NAC increases striatal area occupied by TH-positive terminals in SNCA-overexpressing mice at 12 months of age. A–D.
Representative images of TH-immunostained 30 mm sections of alanine or NAC-treated wild-type or transgenic mouse striatum. A. Wild-type, alanine
treated; B. Wild-type, NAC treated; C. Transgenic, alanine treated; D. Transgenic, NAC treated. E. Density of TH-positive terminals in the striatum of
alanine or NAC-treated wild-type or transgenic mouse striatum. F. Density of DAT-positive terminals in the striatum of alanine or NAC-treated wild-
type or transgenic mouse striatum. Data in E and F were analyzed using a 2-tailed Student’s t-test. All relevant statistically significant comparisons are
indicated on the graph. WT ALA N=4, WT NAC =6, TG ALA =4, TG NAC =3.
doi:10.1371/journal.pone.0012333.g001
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protection by NAC in SNCA overexpressing mice against loss of
TH+ terminals remains significant even after a conservative
Bonferroni correction for multiple comparisons (3 measures of
striatal dopaminergic innervation: percentage of area covered by
TH+ terminals, percentage of area covered by DAT+ terminals,
and striatal dopamine).
NAC significantly reduced the amount of overexpressed human
SNCA protein in the cortex and striatum of PDGFb-SNCA
transgenic mice (Fig. 2E–2H). The mechanism of this effect is yet
to be elucidated. NAC can exert antioxidant effects directly by
acting as a reducing agent and indirectly by increasing glutathione
synthesis [25]. Glutathione levels in the SN were increased after 5–
7 weeks of NAC supplementation but this increase was not seen at
1 year (Fig. 3 & 4). Glutathione levels in the cortex were
unchanged by NAC treatment at either time-point. The
dopaminergic SN is a region of high oxidative stress compared
to the non-dopaminergic cortex [49]. SN GSH levels were higher
in the NAC treated groups for both wild type and PDGFb-SNCA
transgenic mice, but this increase only reached significance in the
case of PDGFb-SNCA mice. The high levels of oxidative stress in
the SN may be compounded by the presence of increased SNCA
in the PDGFb-SNCA transgenics, and this increased oxidative
stress may ‘‘prime’’ the cells of the SN in the SNCA overexpressing
mice to upregulate glutathione synthesis when provided with
additional cysteine precursor, whereas this may be less necessary in
cortical cells.
Since glutathione levels were not altered by NAC in the cortex,
it is likely that the observed reduction in anti-SNCA immunore-
activity in the cortex of PDGFb-SNCA transgenic mice after
treatment with NAC is independent of any effects of NAC on
glutathione synthesis. Levels of SNCA protein have been found to
increase upon exposure to oxidative stress [50], potentially
through stabilization of SNCA by oxidative ligation to dopamine
[19]. Therefore it is feasible that direct antioxidant effects of NAC
may have reduced levels of SNCA protein. However, since
glutathione was transiently increased in the SN of NAC treated
PDGFb-SNCA mice after 5–7 weeks of supplementation (but not
after 1 year), we cannot completely exclude the possibility that
even a transient rise in glutathione may have had lasting effects.
Long-term treatment with NAC affected NFkB signaling in the
brain by increasing cytoplasmic retention of NFkB( Fig. 5) thus
preventing its action as a transcription factor, which requires
translocation to the nucleus. Increased activation of NFkB may
contribute to the pathology in models of Parkinson’s disease [39–
41,51]; therefore, it is possible that protection of striatal TH+
fibers by NAC treatment may be linked to reduced NFkB activity
in these animals. Recently published work in the PDGFb-SNCA
transgenic line [52] has demonstrated that SNCA is transmitted to
astrocytes from neurons, and that the accumulation of SNCA in
astrocytes leads to an increased microglial response. Other in vivo
work also demonstrates that the selective expression of SNCA (in
this case the A53T mutant) in astrocytes leads to increased
inflammatory responses and microglial activation resulting in
significant dopaminergic cell loss [53]. In addition, NFkB
inhibitory peptides have been shown to inhibit MPP+ induced
activation of NFkB in astrocytes and microglia, which diminished
the effects of inflammation and protected the nigrostriatum against
Figure 2. Treatment with NAC Reduces Levels of SNCA in PDGFb-SNCA Transgenic Mice. A–D. Representative images of human SNCA-
immunostained 30 mm sections of alanine or NAC treated wild-type or transgenic mouse cortex. A. Wild-type, alanine treated; B. Wild-type, NAC
treated; C. Transgenic, alanine treated; D. Transgenic, NAC treated. E. Human SNCA staining intensity (integrated density) of the cortex of wild-type
and transgenic mice treated with either alanine or NAC normalized to intensity of staining of the corpus callosum on the same brain section. WT data
is shown to demonstrate the level of non-specific background staining. F. Quantification of the number of intensely stained cells per cortical regiono f
interest. G. Human SNCA staining intensity (integrated density) of the striatum of wild-type and transgenic mice treated with either alanine or NAC
normalized to intensity of staining data from the corpus callosum of the same brain section. H. Quantification of the average number of intensely
stained cells per striatal region of interest. Because of low numbers of SNCA-positive cells in the striatum, ROI data from three separate striatal
sections were averaged. Data in E–H were analyzed using a 2-tailed Student’s t-test. All relevant statistically significant comparisons are indicated on
the graph. All groups N=4.
doi:10.1371/journal.pone.0012333.g002
Figure 3. SNCA-Overexpressing Mice Treated with NAC for 5–7 Weeks Exhibit Increased Glutathione in the Substantia Nigra but
not in Cortex. A. Levels of total glutathione in the Substantia substantia nigra (SN) B. Levels of total glutathione in the cortex (Ctx) of SNCA
overexpressing mice (TG) versus wild-type littermate controls (WT) exposed to drinking water supplemented with NAC or control drinking water
supplemented with alanine (ALA). Data were analyzed using a 2-tailed Student’s t-test. All relevant statistically significant comparisons are indicated
on the graph. WT ALA N=6, WT NAC N=6, TG ALA N=5, TG NAC N=6.
doi:10.1371/journal.pone.0012333.g003
NAC Preserves DA Terminals
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12333MPTP-induced toxicity [51]. Therefore, the reduction of SNCA
expression and inhibition of NFkB in glial cells may be a valid
strategy for neuroprotection in PD. In this work, we used gross
dissections containing a mixed population of both neurons and glia
to determine the cellular compartmentalization of NFkB; further
studies to isolate the glial population in order to determine the glial
cell SNCA load and level of NFkB activation in response to NAC
may provide valuable insight into the mechanism of NAC-
mediated neuroprotection in this model.
A limitation of the current study is that we were unable to
confirm behavioral deficits associated with SNCA overexpression
in this mouse model (Fig. 6 & 7), and thus cannot draw any
conclusions regarding behavioral correlates of the protection by
NAC of striatal TH+ fibers. Previous work with this transgenic line
indicated that line D SNCA-overexpressing mice exhibited a
significant deficit in motor performance compared to their wild-
type counterparts [20]. We did not replicate the previous result in
this study. The reasons for the increased mean latency to fall
across all groups in this work compared to the prior study, despite
attempts to follow a standardized protocol, are unclear. This
discrepancy highlights the difficulty in quantitative comparisons of
behavioral testing results between different laboratories. It will be
important to test the protective effect of NAC in other SNCA
overexpressing mammalian models of PD that display a more
robust behavioral phenotype as well as loss of DA neurons [54–
57].
NAC is used in humans to treat acetaminophen toxicity [58],
and oral supplementation with NAC has been well-tolerated, with
promising results for a possible disease-modifying effect in a 6-
month controlled trial in patients with Alzheimer’s disease [34].
The results presented here demonstrate a neuroprotective effect of
oral NAC supplementation, which may be linked to lowering of
SNCA levels and mediated in part by increased cytoplasmic
sequestration of NFkB, in a chronic degenerative animal model of
PD, further strengthening the arguments in favor of consideration
of testing NAC as a potential neuroprotective agent for PD.
Materials and Methods
Mice
All mice in this study were housed and treated according to the
guidelines for the care and use of laboratory animals issued by the
Harvard Medical School Institutional Animal Care and Use
Committee. A male transgenic mouse overexpressing wild-type
SNCA (NACP140) from the PDGFb promoter (line D;[20]) was a
kind gift from Pamela McLean (Massachusetts General Hospital).
The male was bred with B6D2F1 females (Taconic) to establish
the colony. Male offspring expressing the transgene were crossed
with wild-type female littermates to maintain one copy of the
transgene in subsequent offspring. Male mice were used in all
subsequent experiments.
Genotyping
Genomic DNA was extracted from the ear-punch taken for
identification purposes at weaning using the salt-out procedure or
10 minute DNA kit (Crystalgen). PCR primers and amplification
protocol were as previously reported [20].
Water supplementation
Male transgenic or wild-type littermates were randomized to ad
lib drinking water supplemented with 40 mM NAC or control
drinking water with 40 mM alanine at weaning, and remained on
supplemented water until sacrifice. Water with NAC or alanine
was pH adjusted to pH 7.4 with sodium hydroxide [59] and fresh
water was provided thrice weekly. Control drinking water was
supplemented with 40 mM alanine, a hydrophillic amino acid,
similar in structure to, but lacking the thiol group of cysteine.
40 mM NAC supplemented in this manner has been shown to
Figure 4. Early increases in SN glutathione after NAC treatment are not seen after 12 months of treatment. Levels of total glutathione
in the striatum (Str), substantia nigra (SN) and frontal cortex (Ctx) of SNCA overexpressing mice (TG) versus wild-type littermate controls (WT) exposed
to drinking water supplemented with NAC or control drinking water supplemented with alanine (ALA) from weaning through 1 year of age. Though
levels of glutathione are consistently lower in the SN compared to Str or Ctx at 1 year of age, there are no significant differences between WT versus
TG mice, or between ALA versus NAC treated mice. WT ALA N=4, WT NAC N=5, TG ALA N=3, TG NAC N=3.
doi:10.1371/journal.pone.0012333.g004
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C57BL/6 mice, a dose that reduces the accumulation of DNA
adducts in mice treated with various carcinogens [60].
Immunohistochemisty
Cryoprotected brains were cut on a freezing microtome to
generate sections of 30 mm thickness that were analyzed for the
percentage of striatal area occupied by TH-immunopositive or
DAT-immunopositive terminals as previously described [20].
Sections were immunostained for human SNCA with a mouse-
on-mouse kit (Vector Labs) according to the manufacturer’s
protocol using a monoclonal anti-human SNCA antibody with
minimal cross-reactivity to mouse SNCA (Cell Sciences Mouse
Anti-Human Alpha Synuclein Clone Syn 211 mAb) at a
concentration of 1:500.
Synuclein Densitometry and Particle Analysis
Sections were imaged using the Axioscop (Zeiss) microscope at
106 magnification using fixed exposure on the SPOT RTkE
(Diagnostic Instruments, Inc) imaging system. For densitometric
analysis of each section, a region of cortex in the area of M2 was
analyzed. The investigator was blinded to genotype and treatment
status throughout the process of image examination and
acquisition. Gross observation of positively stained slides indicated
specific staining that covered most of the section with only the
corpus callosum negative for anti-SNCA immunoreactivity. For
this reason the corpus callosum was chosen as a control region to
control for differences in background staining. Using Adobe
Photoshop a series of eight regions of interest (ROI) measuring
50650 pixels were used. Eight ROIs of 50650 pixels were chosen
since these measurements encompassed the width and length of
the corpus callosum at its narrowest part for images taken at 610
magnification. Integrated density measurements were obtained for
both the corpus callosum and cortical region. After subtracting the
average integrated density value of the corpus callosum from the
integrated density values obtained from the cortical ROIs of that
sample and analyzed the results for all four groups using a 2-way
ANOVA. As expected, background values from cortex of wild-
type animals, which do not express human SNCA, were low. To
investigate only the effect of NAC on PDGFb-SNCA mice we
performed a two-tailed t-test to compare the difference between
this treatment group and PDGFb-SNCA mice treated with
alanine. The same strategy was employed to analyze SNCA-
immunoreactivity in the striatum. The difference in absolute
intensity readings between the cortical and striatal samples
demonstrates that the striatal region has much higher non-specific
background values for integrated density, as seen in the values
obtained for WT animals which do not express human SNCA.
Microscopic observation of PDGFb-SNCA samples stained for
human SNCA revealed the obvious presence of highly SNCA-
immunopositive cells in both cortex and striatum. The number of
these cells per ROI was quantified using the ‘Particle Analysis’
function in ImageJ (NIH, USA). The threshold intensity was set to
include those cells that were seen by eye to be positively stained for
SNCA and to discount the surrounding background stain. In
ImageJ this corresponded to a set threshold of baseline-75 for the
cortical region and baseline-24000 for the striatal region. A ROI of
6006600 pixels was set and the ‘Count Particle’ function (with
‘Size (pixel‘2)’ set to 50-infinity and ‘Circularity’ set to 0–1) used to
log each cell of the required intensity within this ROI. This
method of quantification yielded extremely few false positive cells
in wild type animals (average =1.5 cells/ROI), therefore the data
for PDGFb-SNCA transgenics treated with either alanine or NAC
were compared using a two-tailed t-test.
Tissue preparation and western blot analysis
Animals were overdosed with ketamine/xylazine and intracar-
diac-perfused with ice-cold saline. The brains were removed,
placed into a chilled brain matrix and sliced into 1 mm thick
coronal sections on ice. The sections were then placed into ice-cold
saline. The striatum, and SN were dissected out on a chilled glass
dish on ice. Equivalent sized pieces of cortex were also taken from
each of the slices containing the striatum and substantia nigra.
Tissue samples were homogenized in ice-cold lysis buffer using the
TissueLyser LT with 5 mm stainless steel beads (Qiagen). NE-
Figure 5. Long-term NAC treatment affects sub-cellular local-
ization of NFkB. A. 2.5 mg of cytoplasmic protein lysate from the
cortex of 3 alanine- and 3 NAC-treated PDGFb-SNCA mice was run on a
10-well 4–15% SDS-PAGE gel (Bio-Rad). After transfer, the membrane
was cut around the 50 kD marker and probed with anti- NFkB p65
antibody (Santa Cruz) and anti-b-actin antibody (Santa Cruz). 2.5 mgo f
nuclear protein lysate was run on a separate 10-well 4–15% SDS-PAGE
gel and the treated in the manner outlined above. In both cases a single
65 kDa band was observed for NFkB and a single 43 kDa band was
observed for b-actin. B. Band quantification of cytoplasmic NFkB
normalized to b-actin levels. C. Band quantification of nuclear NFkB
normalized to Histone H3 levels. Data were analyzed using a 2-tailed
Student’s t-test. All relevant statistically significant comparisons are
indicated on the graphs. The experiment was repeated three times;
representative results from a 1 minute exposure of both blots are
shown.
doi:10.1371/journal.pone.0012333.g005
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Scientific) were used according to the manufacturer’s instructions
for the extraction of nuclear and cytoplasmic proteins. For whole
cell lysate, tissue was homogenized in 50 mM Tris-HCl (pH 7.4),
150 mM NaCl and 1% Triton-X 100 supplemented with protease
inhibitors to a final concentration of 16(Sigma-Aldrich). Protein
concentrations were determined by Bicinchoninic Acid (BCA)
Assay (Thermo Scientific) according to the manufacturer’s
instructions. Proteins were separated by SDS-PAGE on a Tris-
HCl 4–15% gradient gel (Bio-Rad) according to standard
protocols. The membranes were blocked with 5% non-fat milk
in either 16 PBS-0.1%Tween or 16 TBS-0.1%Tween. Primary
antibodies were diluted in blocking solution in the following
manner: rabbit anti-NFkB p65 (A) (sc-109 Santa Cruz) 1:100;
mouse anti-b-actin (C4) (sc-47778 Santa Cruz) 1:1000; rabbit
PDGFb (H-55) (sc-7878 Santa Cruz) 1:100; rabbit Histone H3
(#9715 Cell Signaling Technology) 1:1000 and incubated on the
membranes with rocking overnight at 4uC. HRP conjugated anti-
mouse IgG-HRP or anti-rabbit IgG (Santa Cruz and Cell
Signaling Technology) were diluted 1:1000 in blocking buffer
and incubated with the membranes at room temperature for
1 hour. The LumiGOLD ECL Western Blotting Detection Kit
(SignaGen) was used according to manufacturer’s instructions and
the blots were imaged by exposure on Amersham Hyperfilm ECL
(GE Healthcare). Band densities were quantified using Adobe
Photoshop. Briefly, the image was inverted and the freehand
selection tool was used to outline each band. Photoshop
automatically computed the integrated density of each band.
The integrated density of each band of interest was normalized to
the integrated density for the loading control of that band.
Glutathione assay
Total glutathione was measured by a kinetic spectrophotometric
assay based on the reduction of 59-59-dithiobis(2-nitrobenzoic acid)
(DTNB) measured by change in absorbance at 412 nm as
previously described [61–63], modified for a 96-well plate format,
with each sample measured in duplicate or triplicate. Concentra-
tions of total glutathione (pmol/mg protein) were calculated from
a glutathione standard curve run with each experiment. Protein
concentration was measured using a BCA Protein Assay Kit
Figure 6. Performance on the accelerating Rotarod was unaffected by SNCA-overexpression or by chronic NAC treatment. Wild-type
(WT) and SNCA-overexpressing (TG) mice treated with either Alanine (ALA) or NAC were tested at 1 year of age on a Rotarod (Ugo Basile) accelerating
from 2–40 rpm over a period of 240 seconds. There were no significant differences between the groups tested. WT ALA N=13, WT NAC N=14, TG
ALA N=12, TG NAC N=16.
doi:10.1371/journal.pone.0012333.g006
Figure 7. Performance on the Pole Test was unaffected by SNCA-overexpression or NAC treatment. A. Time for the mouse to turn on
the pole and face downwards (Tturn). B. Time for the mouse to reach the bottom of the pole (TLA). There were no significant differences between the
groups tested. WT ALA N=12, WT NAC N-12, TG ALA N=13, TG NAC N=16.
doi:10.1371/journal.pone.0012333.g007
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and total cellular glutathione was normalized to the protein
content of the sample before calculating the total glutathione
content compared to non-NAC treated animals.
Rotarod Testing
The rotarod is an extensively used test of motor coordination
[20,64,65]. Mice were tested in the manner outlined in the initial
paper describing a locomotor deficit in line D PDGFb-SNCA mice
[20]. Briefly, mice were trained on a rotarod for mice (Ugo Basile,
Biological Research Apparatus, Varese, Italy) accelerating from 2–
40 rpm over a period of 240 seconds for four consecutive days
with five repetitions of the task, separated by rest period of 15
minutes, each day. The fifth day constituted the test day and the
mice were tested on the same experimental paradigm for a total of
seven trials. The average latency to fall was plotted for each
genotype for each of those seven test trials.
Pole Test
The pole test is used to assess motor function in mouse models
of basal-ganglia related disorders [66–68]. Mice were placed
facing upwards at the top of a vertical pole (50 cm in length, 1 cm
in diameter) that had been covered with surgical tape to provide a
rough surface and capped with a flat plastic disc to prevent the
mouse from traversing the top of the pole. The base of the pole
was placed in the home cage. The times for the mouse to turn and
face downwards (TTURN) and for the mouse to descend into the
home cage (TLA), were recorded with a maximum time of 120 s.
Mice were trained on the task for two days with five trials on each
day and tested for five trials on the third day. If the mouse fell from
the pole or was unable to climb down the pole in any given trial,
the longest time from among that animal’s previous trials was
recorded for the unsuccessful run. This is consistent with
previously published methods of analysis of pole test results [69],
and an alternative method of excluding such trials did not
significantly alter the results in our study.
Statistical Analyses
Except where otherwise noted, for each of the reported
assessments, mean results were compared between groups using
a 2-tailed unpaired t-test with a threshold for significance at 0.05.
Supporting Information
Figure S1 NAC treatment does not affect cellular levels of
PDGFb. A. 1 mg of whole-cell protein lysate from 3 alanine- and 3
NAC-treated SNCA-PDGFb striatal samples or B. SN samples
were run on a 15-well 4–15% SDS-PAGE gel. After transfer, the
membrane was probed with anti- PDGFb antibody (Santa Cruz)
and anti-b-actin antibody (Santa Cruz). A single 25 kDa band
representing the PDGFb homodimer was seen in most of the
striatal samples. The 25 kDa band was seen alongside a 27 kDa
band in the SN samples. The 27 kDa band likely represents the
PDGFab heterodimer. A single 43 kDa band was seen in for
b-actin C. Band quantification of striatal NFkB normalized to b-
actin levels. D. Band quantification of SN NFkB normalized to b-
actin levels. Only the lower homodimer band was quantified. The
experiment was repeated three times. Representative results from
a 1 minute exposure are shown. Data were analyzed using a 2-
tailed Student’s t-test and no statistically significant differences
were found for alanine compared to NAC treated striatum or SN.
Found at: doi:10.1371/journal.pone.0012333.s001 (0.55 MB TIF)
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